Clinical characteristics at baseline
| Variable | Discordant moderate AS (N=150) | Concordant moderate AS (N=640) | P value |
| Age (years) | 74±10 | 70±12 | <0.001 |
| Male gender, n (%) | 88 (58.7%) | 322 (50.3%) | 0.065 |
| Body mass index (kg/m²) | 25.0±4.6 | 25.7±6.6 | 0.213 |
| Body surface area (m2) | 1.70±0.25 | 1.69±0.23 | 0.510 |
| Hypertension, n (%) | 116 (77.3%) | 493 (77.2%) | 0.962 |
| Diabetes mellitus, n (%) | 59 (39.3%) | 201 (31.4%) | 0.063 |
| Dyslipidaemia, n (%) | 112 (74.7%) | 486 (76.1%) | 0.721 |
| Coronary artery disease, n (%) | 104 (69.3%) | 278 (43.4%) | <0.001 |
| Previous myocardial infarction, n (%) | 45 (30.0%) | 78 (12.2%) | <0.001 |
| eGFR <60 mL/min/1.73 m², n (%) | 81 (54.0%) | 257 (41.1%) | 0.004 |
| Chronic lung disease, n (%) | 16 (10.7%) | 38 (5.9%) | 0.039 |
| Atrial fibrillation, n (%) | 53 (35.3%) | 160 (25.0%) | 0.010 |
| Beta blocker, n (%) | 82 (55.0%) | 317 (49.5%) | 0.226 |
| ACE inhibitor/ARB, n (%) | 86 (58.1%) | 310 (48.4%) | 0.034 |
| Calcium channel blockers, n (%) | 49 (32.9%) | 269 (42%) | 0.040 |
| Diuretics, n (%) | 68 (45.6%) | 207 (32.3%) | 0.002 |
| Statins, n (%) | 123 (82.6%) | 461 (72.0%) | 0.008 |
ACE, angiotensin converting enzyme; ARB, angiotensin-receptor blocker; AS, aortic stenosis; eGFR, estimated glomerular filtration rate.